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Pipecuronium bromide is a long-acting nondepolariz-ing steroidal neuromuscular blocking agent (NMBA), and a bisquaternary ammonium compound similar 
to pancuronium bromide.1,2 Pipecuronium was introduced 
in clinical practice in the late 1970s.3 Unlike pancuronium, 
pipecuronium has few if any cardiovascular side-effects4 
and histamine release does not appear to be a problem.5 The 
average effective dose of the neuromuscular agent producing 
a 95% reduction in twitch height (ED95) for pipecuronium is 
approximately 0.045 mg/kg (0.035–0.059 mg/kg).6,7 The onset 
of action (mean time from start of injection to 90% twitch 
suppression or to maximum block) varies from 2.0 minutes 
(2 × ED95) to 6.3 minutes (1 × ED95)8–10 and the clinical dura-
tion (mean time to 25% recovery of the twitch height) varies 
from 29 minutes (1 × ED95) to 110 minutes (2 × ED95), as it is 
influenced by the dose and the anesthetic technique used.8–10
Pipecuronium undergoes very little metabolism and is 
excreted by the kidney and the liver.11 Owing to its relatively 
long duration of action and to the residual postoperative 
neuromuscular block (RPONB), the use of pipecuronium 
was discontinued in the United States and in several 
European countries. Because of its excellent safety profile, 
the use of pipecuronium has been maintained in several 
countries including China, Russia, Brazil, and Hungary, 
among others. Its safe use, however, is dependent on the 
availability of a reliable reversal drug. Although widely 
used, there are concerns with the use of neostigmine for 
reversal. These include undesirable muscarinergic side 
effects, limited ability to antagonize profound neuromuscu-
lar block (NMB),12 or prolonged time to full recovery, even 
when administered with 4 palpable responses to train-of-
four (TOF) stimulation.13,14 Because of these limitations with 
neostigmine, investigators continue to seek alternatives for 
reversal of NMB.15 Sugammadex, a modified γ-cyclodextrin 
compound, has emerged as a new reversal drug, and acts as 
a specific encapsulator of steroidal relaxants.14 Sugammadex 
readily reverses the effect of rocuronium or vecuronium by 
encapsulating the relaxant molecules in the plasma, lower-
ing the concentration of free drug. The NMBA then diffuses 
away from prejunctional and postjunctional nicotinic ace-
tylcholine receptors based on concentration gradients.14,16
The encapsulation of steroidal relaxants by sugamma-
dex is a one-to-one molecular interaction depending on the 
affinity of sugammadex for these substances. Sugammadex 
has a high affinity for pipecuronium. As pipecuronium is 
about 6 to 7 times more potent than rocuronium,9,17 fewer 
molecules are required to achieve a comparative blockade 
than in the case of rocuronium. The ability of sugamma-
dex to reverse pipecuronium-induced NMB in anesthe-
tized patients remains unknown. Furthermore, no study 
BACKGROUND: Pipecuronium is a steroidal neuromuscular blocking agent. Sugammadex, a 
relaxant binding γ-cyclodextrin derivative, reverses the effect of rocuronium, vecuronium, and 
pancuronium. We investigated whether sugammadex reverses moderate pipecuronium-induced 
neuromuscular blockade (NMB) and the doses required to achieve reversal.
METHODS: This single-center, randomized, double-blind, 5-group parallel-arm study comprised 
50 patients undergoing general anesthesia with propofol, sevoflurane, fentanyl, and pipe-
curonium. Neuromuscular monitoring was performed with acceleromyography (TOF-Watch SX®) 
according to international standards. When the NMB recovered spontaneously to train-of-four 
count 2, patients randomly received 1.0, 2.0, 3.0, or 4.0 mg/kg of sugammadex or placebo. 
Recovery time from sugammadex injection to normalized train-of-four (TOF) ratio 0.9 was the 
primary outcome variable. The recovery time from the sugammadex injection to final T1 was the 
secondary end point. Postoperative neuromuscular functions were also assessed.
RESULTS: Each patient who received sugammadex recovered to a normalized TOF ratio of 0.9 
within 5.0 minutes (95% lower confidence interval for the lowest dose 70.1%; for all doses 
90.8%) and 79% of these patients reached a normalized TOF ratio 0.9 within 2.0 minutes (95% 
lower confidence interval for the lowest dose 26.7%; for all doses 63.7%). T1 recovered several 
minutes after the TOF ratio. No residual postoperative NMB was observed.
CONCLUSIONS: Sugammadex adequately and rapidly reverses pipecuronium-induced moderate 
NMB during sevoflurane anesthesia. Once the train-of-four count has spontaneously returned 
to 2 responses following pipecuronium administration, a dose of 2.0 mg/kg of sugammadex is 
sufficient to reverse the NMB.  (Anesth Analg 2015;XXX:00–00)
Reversal of Pipecuronium-Induced Moderate 
Neuromuscular Block with Sugammadex in the Presence 
of a Sevoflurane Anesthetic: A Randomized Trial
Edömér Tassonyi, MD, PhD, DSc,* Adrienn Pongrácz, MD,* Réka Nemes, MD,* László Asztalos, MD,* 
Szabolcs Lengyel, PhD, DSc,† and Béla Fülesdi, MD, PhD, Dsc*
From the *Department of Anesthesiology and Intensive Care, University 
of Debrecen, Debrecen, Hungary; and †Department of Ecology, Hungarian 
Academy of Sciences, Centre for Ecological Research, Debrecen, Hungary.
Accepted for publication January 29, 2015.
Funding: The present work was supported from departmental funds only, no 
external sources were received.
The authors declare no conflicts of interest.
Reprints will not be available from the authors.
Address correspondence to Béla Fülesdi, MD, PhD, Dsc, Department of An-
esthesiology and Intensive Care, University of Debrecen, Nagyerdei krt. 98, 
Debrecen H_4032, Hungary. Address e-mail to fulesdi@med.unideb.hu.
RESEARCH REPORT
Copyright © 2015 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
Sugammadex Reversal of Pipecuronium-Induced NMB
2   www.anesthesia-analgesia.org ANESTHESiA & ANAlgESiA
has investigated the appropriate dose of sugammadex to 
reverse NMB from pipecuronium.
The aim of this study was to establish the dose of 
sugammadex required to reverse a moderate (train-of-four 
count 2 [TOFC-2]) pipecuronium-induced NMB in surgi-
cal patients. We also investigated whether reversing the 
NMB from pipecuronium with sugammadex influences the 
occurrence of RPONB or recurrent NMB. We hypothesized 
that the dose of sugammadex recommended for the rever-
sal of rocuronium-induced block (1.0–4.0 mg/kg) would 
also reverse the effect of pipecuronium. We also hypoth-
esized that sugammadex reversal of pipecuronium NMB 
would result in minimal RPONB or recurrent NMB.
METHODS
Trial Design and Participants
This single-center, randomized, double-blind, 5-group 
 parallel-arm study was approved by the local ethics committee 
at the University of Debrecen, Hungary (DEOEC RKEB/IKEB 
3585-2012) and by the National Institute of Pharmaceutics 
(Országos Gyógyszerészeti Intézet, Budapest, Hungary). The 
study is classified under EUDRACT number 2012-000 29-14.
The investigations and data collection were performed 
at the University Hospital of Debrecen, Hungary, between 
2012 August and 2014 January. Data reporting follow the 
CONSORT 2010 recommendations.a
Fifty participants were recruited from patients scheduled 
for routine elective surgery and gave written, informed con-
sent to participate. Subjects were randomly assigned to 1 of 
the 5 study groups to receive 1.0, 2.0, 3.0, and 4.0 mg/kg of 
sugammadex or 0.9% saline (Fig. 1). Eligibility criteria were 
age of 18 to 65 years, body mass index 18.5 to 25.0 kg/m2, 
ASA physical status I to III, and scheduled for elective sur-
gery with an expected duration of 90 minutes or more of gen-
eral anesthesia that required tracheal intubation. Exclusion 
criteria were suspected difficult airway, bronchial asthma, 
chronic obstructive pulmonary disease, neuromuscular dis-
ease, suspected malignant hyperthermia, significant hepatic 
or renal dysfunction, glaucoma, allergy to drugs used in this 
trial, and taking medication known to influence the effect 
of NMBAs. Additional exlusions included patients who 
had participated in another study within the past month, or 
pregnant or breastfeeding patients.
Interventions and Neuromuscular Monitoring
Patients received 7.5 mg of midazolam orally 1 hour before 
induction of anesthesia. In the operating room, an IV cannula 
was inserted in a forearm vein. Noninvasive blood pressure, 
electrocardiogram, and oxygen saturation measurements 
were started. Induction of anesthesia consisted of IV propo-
fol (1.5–2.0 mg/kg) and fentanyl (2.0 μg/kg). Maintenance 
of anesthesia consisted of inhaled sevoflurane (1.0–1.3 aver-
age vol%) in air–oxygen mixture and IV fentanyl according 
to clinical need. Patients’ lungs were manually ventilated 
using a facemask until intubation of the trachea. Oxygen 
saturation was maintained above 96%, normocapnia was 
ensured, and body temperature was maintained at 36°C 
or higher using forced air warming system (Bair-Hugger® 
Arizant Healthcare Inc., Eden Prairie, MN).
The TOF-Watch-SX® acceleromyograph (Organon 
Teknika B.V., Boxtel, Holland) was used for monitoring 
adductor pollicis muscle contractions in response to ulnar 
nerve stimulation. The piezoelectric probe of the accelero-
myograph was attached to the tip of the thumb. A hand 
adapter ensured preload of the thumb while ensuring that 
it continued to return to its exact original position.18 The 
forearm and the fingers were immobilized, and surface 
skin electrodes were placed over the ulnar nerve proxi-
mal to the wrist. A TOF mode of stimulation was started 
and repeated every 15 seconds for 3 minutes followed by 
a 5-second tetanic train of 50 Hz. Two minutes later, auto-
matic calibration was performed (CAL-2 to set out supra-
maximal current intensity and calibration of the device). 
TOF stimulation was recommenced (supramaximal square 
wave stimuli of 0.2 millisecond duration at 2 Hz frequency) 
until the signal was stable. If the signal was not stable, the 
calibration was repeated. Data were recorded and stored on 
a computer using TOF-Watch SX software version 2.2 INT 
(Organon Ireland Ltd. Dublin, Ireland). Skin temperature 
was measured at the forearm near to the wrist and main-
tained above 32°C. Once the neuromuscular recording was 
stable, 0.06 mg/kg (about 1.3 × ED95) pipecuronium was 
injected IV, and the trachea was intubated when the muscle 
response to TOF stimulation disappeared. During surgery, 
0.01 mg/kg of pipecuronium was given at TOF count 1 to 
maintain muscle relaxation as needed. The TOF stimula-
tion was automatically repeated every 15-second interval 
during the procedure. At the end of surgery, patients were 
allowed to spontaneously recover from the NMB. Once the 
TOF-Watch SX monitor displayed 2 responses to TOF stim-
ulation, a member of the investigative team (the anesthesi-
ologist, who had prepared the study drug), injected it upon 
the request of the anesthesiologist who was responsible 
for the patient. The anesthesiologists caring for the patient 
remained blinded to the drug. The TOF ratio (T4/T1) and 
T1 amplitude (the first of 4 twitches to TOF stimulation) 
were recorded and analyzed later. Once the displayed TOF 
ratio was 1.0, sevoflurane was discontinued. The trachea 
was extubated when the patient emerged from anesthesia.
For incomplete recovery (stagnation of TOF ratio at <0.9 
for at least 5 minutes), during the first 45 minutes following 
emergence from anesthesia, rescue reversal of NMB con-
sisted of 0.015 mg/kg atropine and 0.05 mg/kg neostigmine.
Postoperative Assessment
After extubation of the trachea, patients were transferred 
to the recovery room. The stimulator was set on standby 
mode during the transport and the forearm and the hand 
adapter’s positioning were secured. In the recovery room, 
a separate anesthesiologist, blinded to the study drug, per-
formed acceleromyographic and clinical assessments of the 
neuromuscular function.
Postoperative acceleromyographic recordings were com-
menced (time zero) without recalibration of the device and 
were repeated every 20 minutes until 60 minutes. At each 
point in time, 3 consecutive TOF stimuli were delivered at 
15-second interval and the averages of 3 evoked TOF ratios 
were considered. Data were recorded and stored on a com-
puter, and analyzed offline. TOF ratios less than 0.9 were 
defined as RPONB.aAvailable at: www.consort-statement.org.
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Oxygen saturation, noninvasive blood pressure, elec-
trocardiogram, and respiratory rate were monitored. In 
responsive patients, head lift, arm-leg raise, hand grip, 
eye opening, smiling, tongue protrusion, coughing, dou-
ble vision, and self-assessment of strength were evaluated 
every 20 minutes.19
Any sign of muscle weakness and critical respiratory 
or circulatory events were noted. After discharge from the 
recovery room, as a safety measure, patients were observed 
for 24 hours to detect late adverse events.
Outcome Measures
TOF ratio and the T1 height were assessed as efficacy vari-
ables. Normalized values of these parameters were calcu-
lated by dividing the recorded values at recovery by the 
baseline values before administration of pipecuronium.
The primary outcome measure was the time from the start 
of injection of the study drug to normalized TOF ratio of 0.9.
The secondary outcome measure was the time from the start 
of injection of the study drug to final T1 (the first of maximal 
T1 values at stable signal).
An alternative outcome measure was the time necessary to 
achieve nonnormalized TOF ratio of ≥1.0 (the first of 3 con-
secutive responses).
The postoperative outcome measure was RPONB defined 
as nonnormalized TOF ratio less than 0.9, with or without 
muscle weakness or critical respiratory events.
Sample Size
We assumed the spontaneous recovery time from a 
0.06 mg/kg pipecuronium-induced block would be 60 ± 30 
minutes (mean ± SD)20 and a reduction of the recovery time 
by 10 minutes with the lowest dose (1.0 mg/kg) of sugam-
madex. Using a Type 1 error rate (α) of 0.05, a sample size 
(n) of 6 in the treatment groups would be needed to reach a 
power of 0.8 and n of 8 would result in a power of 0.9. We 
included 10 patients in each group to allow for dropouts.
Randomization and Blinding
Subjects were randomly allocated to 5 study groups to 
receive 1.0, 2.0, 3.0, and 4.0 mg/kg of sugammadex or pla-
cebo. Permuted-block randomization was used to ensure 
equal numbers of subjects per group.21 A sealed envelope 
method was used to assign participants to study groups. 
A designated anesthesiologist prepared the study drug and 
administered it in the operating room, while the patients 
and the anesthesiologists attending to the patient periopera-
tively remained blinded to the group to which the patients 
had been assigned.
Statistical Methods
The Fisher exact test was used to compare proportions across 
categories of 2 × 2 contingency tables. Ninety-five percent 
confidence intervals (CIs) around single proportions were 
estimated using the Wilson score method, or when 100% 
of events were observed, the Clopper-Pearson method. For 
continuous variables, parametric statistical tests were used 
if their assumptions were met by the data. The Bartlett test 
was used to check the homogeneity of variances and the 
Shapiro-Wilk test was used to check the normality of residu-
als of the analysis of variance (ANOVA). A P value less than 
0.05 indicated a deviation from homogeneity or normality, 
Figure 1. Study flowchart. The administration of sugammadex (Sug) and placebo was randomized and double blinded. The administration of 
pipecuronium was open. OTI = orotracheal intubation; TOFC-2 = spontaneous recovery to 2 twitches. End-points were normalized train-of-four 
(TOF) 0.9, nonnormalized TOF ≥1.0, and maximal T1. Rescue therapy was neostigmine.
Copyright © 2015 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
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respectively. Given that most background variables (patient 
data, perioperative variables) deviated from normality or 
had nonhomogeneous variances, the Kruskal-Wallis test was 
used to compare background variables across experimental 
groups. Where appropriate, a log transform of response vari-
able data was made to ensure the homogeneity of variances 
or the normality of residuals prior to comparing groups 
with a 1-way ANOVA. For instance, the variances were het-
erogeneous for the recovery time to TOF ratio 0.9 among 
groups (Bartlett χ2 = 129.587, df = 4, P < 0.0001), but were 
homogeneous after a log-transformation (χ2 = 3.077, df = 4, 
P = 0.545). Finally, we compared time to primary and sec-
ondary end points for each dose group with a paired t test. 
All analyses were using statistical software (R statistical 
environment, version 2.15.2).
RESULTS
All enrolled patients were assigned to 1 of the 5 study 
groups.
One minor protocol violation occurred in the 1 mg/kg 
sugammadex group and in the placebo group. One techni-
cal failure occurred in the 4 mg/kg sugammadex group. 
These 3 patients were excluded from the outcome analysis 
but were included in the postoperative follow-up to assess 
residual blockade (Fig. 1). Of the remaining 47 patients 
included in the outcome analysis, 38 received sugammadex.
Table 1 presents the patient demographics of each of the 
5 study groups. Although the low dose sugammadex group 
(1 mg/kg) consisted of 8 female patients and 1 male patient, 
the proportion of males/females did not significantly differ 
between groups (P = 0.1). There was no difference in age, 
body mass index, height, weight, control TOF ratio, con-
trol T1 (%), or ASA physical status score among the 5 study 
groups (P > 0.1).
Recovery Times
Spontaneous Recovery to Moderate Block
Table 2 presents the pipecuronium dose and end-tidal sevo-
flurane concentrations at the time of pipecuronium admin-
istration and at the time of pipecuronium reversal. It also 
presents the time interval from bolus IV administration of 
pipecuronium to the appearance of 2 TOF twitches, the time-
point of study drug or placebo administration. There was 
no difference among groups in the total pipecuronium dose, 
end-tidal sevoflurane concentration at induction, or end-
tidal sevoflurane concentration at the time of antagonism 
with sugammadex (P > 0.3). There was also no difference 
among groups in this time interval between pipecuronium 
administration and the appearance of 2 TOF twitches 
(P = 0.57).
Primary Outcome
Table  3 presents the primary and secondary end-points 
(time in minutes to a normalized TOF ratio of 0.9 and time 
to maximal T1). All patients that received sugammadex, 
including those in the low sugammadex dose (1 mg/kg) 
recovered to normalized TOF ratio of 0.9 in less than 5.0 
minutes (95% lower CI for the lowest dose 70.1%; for all 
doses 90.8%). Seventy-nine percent of patients in all sugam-
madex groups reached normalized TOF ratio 0.9 within 2.0 
minutes (95% lower CI for the lowest dose 26.7%; for all 
doses 63.7%).
As presented in Table 3, there was a weak, but statistically 
significant, difference in the time to TOF ratio 0.9 among the 
sugammadex-treated groups (P = 0.044) because times were 
shorter in the group receiving 3.0 mg/kg sugammadex than 
in the 1.0 mg/kg sugammadex group (P = 0.0497).
In the placebo group, no patient had a satisfactory 
recovery from the NMB with a TOF ratio of 0.2 ± 0.08 
Table 1.  Basic Characteristics
Variable
Sug 1 mg/kg  
(n = 9)
Sug 2 mg/kg  
(n = 10)
Sug 3 mg/kg  
(n = 10)
Sug 4 mg/kg  
(n = 9)
Placebo  
(n = 9)
Sex (males/females)* 1/8 6/4 7/3 4/5 4/5
Age (y), mean ± SD* 49.6 ± 11.3 52.3 ± 11.45 52.4 ± 9.29 52.3 ± 13.50 46.9 ± 15.07
BMI (kg/m2), mean ± SD* 22.2 ± 2.28 23.5 ± 1.9 22.7 ± 2.45 22.3 ± 2.35 23.5 ± 1.61
95% CI 20.7–23.8 22.3–24.7 21.2–24.2 20.8–23.9 22.5–24.6
Median (range) 23 (18–25) 24.5 (20–25) 23.5 (19–25) 22 (18–25) 24 (21–25)
Height (m), mean ± SD* 1.64 ± 0.07 1.73 ± 0.07 1.71 ± 0.07 1.67 ± 0.08 1.69 ± 0.16
Weight (kg), mean ± SD* 58.7 ± 8.67 72.0 ± 10.30 66.3 ± 9.19 63.6 ± 10.16 68.4 ± 14.34
Control TOF ratio, mean ± SD* 1.06 ± 0.05 1.09 ± 0.07 1.08 ± 0.09 1.09 ± 0.06 1.08 ± 0.08
Control T1 (%), mean ± SD* 96.4 ± 9.72 94.6 ± 6.74 98.1 ± 7.19 96.0 ± 7.60 99.4 ± 9.80
ASA score I/II/III* 1/8/0 1/8/1 1/8/1 2/7/0 1/8/0
BMI = body mass index; ASA = American Society of Anesthesiology physical status score; Sug = sugammadex; TOF = train-of-four; CI = confidence interval.*P ≥ 0.1 among the 5 groups.
Table 2.  Anesthetic Management and Times to TOFC-2
Variables
Sug 1 mg/kg 
(n = 9)
Sug 2 mg/kg 
(n = 10)
Sug 3 mg/kg 
(n = 10)
Sug 4 mg/kg 
(n = 9)
Placebo  
(n = 9)
Pipecuronium total dose (mg/kg)* 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.06 ±0.0
Sevoflurane cc. at administration of 
pipecuronium (vol%)* 1.16 ± 0.31 1.05 ± 0.29 0.99 ± 0.17 1.22 ± 0.39 1.11 ± 0.27
Sevoflurane Et. at antagonism (vol%)* 1.27 ± 0.41 1.25 ± 0.52 1.12 ± 0.25 1.37 ± 0.33 1.37 ± 0.27
Time to TOFC-2 (minutes)* 92.5 ± 31.7 111 ± 49.9 120.9 ± 45.5 91.9 ± 30.7 113 ± 57
Mean ± SD; Sug = sugammadex; Et. = end-tidal concentration; TOF = train-of-four; TOFC-2 = spontaneous recovery to 2 twitches.*P > 0.3 among the 5 groups.
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(mean ± SD). Thus, each patient (n = 9) received rescue 
medication (neostigmine) after 32.1 ± 9.9 minutes (mean 
± SD, range: 19.5–45.8, 95% CI: 24.4–39.6). Conventional 
reversal with neostigmine to a normalized TOF ratio of 
0.9 took required 11.6 ± 5.5 minutes (mean ± SD, range: 
2.8–20.3, 95% CI: 7.3–15.9). Given that the aim of the 
analysis was to compare various doses of sugamma-
dex with saline, reversal times from the placebo group 
treated with neostigmine were excluded from the analy-
sis of reversal times.
Secondary Outcome
As presented in Table 3, reversal to final T1 height required 
significantly more time in all sugammadex groups than 
reversal of the corresponding TOF ratio (0.0003 < P < 0.018), 
but there was no significant difference in reversal times 
among the four sugammadex groups (P = 0.327).
Alternative Outcome
Reversal times were not different in the sugammadex 
groups irrespective of whether the end point was normal-
ized 0.9 or nonnormalized TOF ratio 1.0 (P = 0.24).
Postoperative Outcome
During the first 60 minutes of the postoperative course, the 
TOF ratio was never less than 0.9 in any of the sugamma-
dex treatment groups. In fact, the average TOF ratio was 
1.0 or more throughout this assessment period in all treat-
ment groups (Table 4). No early or late adverse events were 
observed.
DISCUSSION
Summary of Results
We evaluated the efficacy of different doses of sugamma-
dex for the reversal of moderate pipecuronium-induced 
NMB in surgical patients. To date, this issue has not been 
investigated. We hypothesized that the doses of sugam-
madex recommended for the reversal of rocuronium- and 
vecuronium-induced block would also reverse the effect of 
pipecuronium.
This study has confirmed our hypothesis, and docu-
mented the efficacy and reliability of sugammadex in doses 
of 1.0 and 2.0 mg/kg for the antagonism of pipecuronium-
induced block that had spontaneously recovered to 2 twitches 
Table 3.  Main Outcome Data: Time to Normalized TOF Ratio, Time to Maximal T1, Time to Raw TOF Ratio 
1.0 and Maximal Normalized T1 at Recovery
Variable
Sug 1 mg/kg  
(n = 9)
Sug 2 mg/kg  
(n = 10)
Sug 3 mg/kg  
(n = 10)
Sug 4 mg/kg  
(n = 9)
Primary end point: Time to normalized TOF ratio 0.9 (minutes)a,b
Mean ± SD 2.3 ± 0.95a 1.7 ± 0.59ab 1.5 ± 0.33b 1.55 ± 0.5ab
95% CI interval 1.7–2.95 1.36–2.09 1.29–1.7 1.22–1.89
Median (range) 2.0 (1.25–4.25) 1.63 (1.0–2.5) 1.5 (1.0–2.0) 1.25 (1.25–2.75)
Secondary end point: Time to maximal T1 (minutes)*
Mean ± SD 8.1 ± 2.8 8.1 ± 5.6 5.72 ± 2.4 4.97 ± 3.24
95% CI interval 7.57–8.53 6.97–9.18 5.22–6.23 2.63–5.64
Median (range) 7.5 (4.0–12.25) 6.63 (3.5–18.25) 5.0 (2.25–9.5) 4.25 (1.25–10.5)
Additional end point: Time to raw TOF ratio 1.0 (minutes)
Mean ± SD 2.4 ± 0.9 2.25 ± 1.72 1.5 ± 0.4 1.66 ± 0.5
95% CI interval 2.25–2.57 1.9–2.58 1.4–1.59 1.55–1.78
Median (range) 2.0 (1.5–3.5) 1.75 (1.0–6.75) 1.5 (1.0–2.0) 1.5 (1.25–2.75)
Maximal normalized T1 at recovery (1/100)
Mean ± SD 0.96 ± 0.14 0.96 ± 0.13 0.94 ± 0.14 1.0 ± 0.16
95% CI interval 0.9–1.0 0.9–1.0 0.9–1.0 1.0–1.1
Median (range) 1.0 (0.77–1.13) 0.99 (0.76–1.11) 0.98 (0.76–1.15) 1.05 (0.75–1.23)
Sug = sugammadex; TOF = train-of-four; CI = confidence interval.
aPaired t tests of primary versus secondary end points within dose groups: 1 mg/kg: P = 0.0004; 2 mg/kg: P = 0.006; 3 mg/kg: P = 0.0003; 4 mg/kg: P = 0.018.
bGroups not sharing lowercase letters are significantly different (Tukey HSD test, P = 0.0497).
Table 4.  Postoperative Neuromuscular Outcome During the First 60 Minutes: Nonnormalized TOF Ratios
Time  
(minutes) Statistics
Sug 1 mg/kg  
(n = 9)
Sug 2 mg/kg  
(n = 10)
Sug 3 mg/kg  
(n = 10)
Sug 4 mg/kg  
(n = 9)
Placebo  
(n = 9)
0 Mean ± SD 1.1 ± 0.07 1.03 ± 0.09 1.1 ± 0.16 1.08 ± 0.10 1.0 ± 0.09
95% CI 1.06–1.15 0.98 1.09 1.0–1.2 1.0–1.15 0.95–1.07
Median (range) 1.1 (0.97–1.23) 1.02 (0.9–1.21) 1.04 (1.0–1.41) 1.1 (0.91–1.21) 1.0 (0.92–1.21)
20 Mean ± SD 1.07 ± 0.09 1.0 ± 0.09 1.08 ± 0.1 1.06 ± 0.09 1.02 ± 0.11
95% CI 1.0–1.13 0.96–1.07 1.0–1.15 1.0–1.13 0.96–1.1
Median (range) 1.08 (0.9–1.2) 1.02 (0.92–1.2) 1.03 (0.98–1.3) 1.06 (0.93–1.2) 1.0 (0.93–1.25)
40 Mean ± SD 1.06 ± 0.01 1.03 ± 0.08 1.08 ± 0.13 1.04 ± 0.11 1.03 ± 0.09
95% CI 1.0–1.13 0.99–1.08 1.0–1.16 0.97–1.12 0.97–1.09
Median (range) 1.05 (0.9–1.2) 1.0 (0.94–1.2) 1.07 (0.92–1.38) 1.02 (0.94–1.18) 1.0 (0.92–1.23)
60 Mean ± SD 1.08 ± 0.09 1.02 ± 0.07 1.08 ± 0.09 1.07 ± 0.04 1.04 ± 0.04
95% CI 1.02–1.14 0.98–1.06 1.03–1.15 1.05–1.11 1.0–1.07
Median (range) 1.07 (0.92–1.3) 1.02 (0.91–1.1) 1.07 (0.99–1.24) 1.06 (1.03–1.14) 1.04 (0.96–1.1)
Sug = sugammadex; TOF = train-of-four; CI = confidence interval.
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of TOF stimulation. In fact, 79% of patients who were given 
sugammadex fulfilled the primary outcome within 2.0 min-
utes, and the remaining 21% reached a normalized TOF ratio 
0.9 within 5.0 minutes. From a practical point of view, recov-
ery of the TOF ratio to ≥0.9 in less than 5 minutes is perfectly 
adequate and, since it can be achieved using 1.0 or 2.0 mg/kg 
of sugammadex, the administration of larger doses (like 3.0 
and 4.0 mg/kg) is not indicated in this situation.
Recovery of T1 to maximum height took 5 to 8 minutes, 
longer than recovery of TOF ratio to 0.9, and exhibited a 
similar trend of dose-effect relationship to the primary out-
come measures (Table 3). Although the delay of T1 recovery 
behind the TOF ratio of 0.9 or 1.0 did not ensure full recov-
ery from the block in this setting,22 there does not appear to 
be any clinical implications of this finding. Indeed, RPONB, 
recurrent NMB, or critical adverse events did not occur dur-
ing the postoperative period (Table 4).
We chose to reverse a moderate (TOFC-2) pipe-
curonium-induced block to be consistent with most inves-
tigations exploring the reversal of other neuromuscular 
blocking agents with sugammadex.16,23,24 We selected the 
doses of sugammadex based on prior work that reported 
doses of 2.0 mg/kg as standard for reversal of mod-
erate rocuronium and vecuronium-induced block,16,24  
1.0 mg/kg as low dose for reversal of rocuronium,13  
3.0 mg/kg as intermediate dose, and 4.0 mg/kg as high 
dose. In the absence of data about the effect of low dose 
sugammadex on pipecuronium block, we assumed that 
insufficient reversal may occur and therefore we chose a 
placebo comparator to distinguish the effect of sugamma-
dex from spontaneous recovery. With regard to the poten-
tial of prolonged effect from pipecuronium, we prepared 
for rescue treatment with neostigmine if recovery was 
incomplete after 45 minutes. This time limit was agreed 
upon with the operating room team. In fact, rescue treat-
ment was employed only in the placebo group approxi-
mately 30 minutes after saline administration and a 
stagnated TOF ratio of around 0.20 for at least 5 minutes. A 
TOF ratio of 0.20 represents a TOFC-4 with significant and 
palpable fade. Despite this considerable degree of spon-
taneous recovery, neostigmine-induced antagonism was 
slow (on average 11–12 minutes). That said, if the TOFC 
is 4 and rapid reversal is unnecessary, administration of 
neostigmine has distinct economic benefits.
Although most relevant publications about sugamma-
dex described uncorrected (nonnormalized) acceleromyo-
graphic TOF ratio 0.9 as reversal end point,16,23,24 actually 
normalized TOF ratio 0.9 is recommended to exclude resid-
ual NMB.25 It is even suggested that the acceleromyographic 
TOF ratio should be 1.0 or greater to exclude clinically rel-
evant paralysis.13,26 In this study, reversal times after sugam-
madex were similar whether normalized TOF ratio 0.9 or 
nonnormalized TOF ratio 1.0 was the end point (Table 3). 
This is in agreement with the results of Capron et al.26 who 
demonstrated that the negative predictive values of accel-
eromyographic TOF ratio of 1.0 and normalized TOF ratio 
of 0.9 are similar to detect residual paralysis and superior to 
nonnormalized TOF ratio 0.9. Normalization, that is, divid-
ing the final TOF recovery value noted at the acceleromyo-
graphic monitor screen by the control value taken before 
the injection of neuromuscular blocking agent, is a complex 
procedure, and therefore direct measurement of TOF 1.0 
displayed on the monitor screen may offer advantages for 
clinical practice by its relative simplicity.
As the TOF ratio reflects the effects of NMBAs at the 
presynaptic site of the neuromuscular junction, the T1 
response reflects the events at the postjunctional endplate 
and exhibits the muscle force generated.27 Accordingly, 
not only the TOF ratio but also the amplitude of the con-
traction (T1 twitch height) should exceed 90% of control 
for neuromuscular recovery to be considered acceptable.28 
Classically, during spontaneous recovery or after anticho-
linesterases, the T1 recovered first followed by the TOF ratio 
soon after then the block ended.28 However, like others,22,29 
we observed reduced T1 twitches in a few minutes after 
sugammadex while TOF ratio 1.0 was reached. The delay 
of T1 twitch behind the TOF ratio recovery is not unique 
to pipecuronium and occurred also when rocuronium was 
antagonized with sugammadex.22,29
Residual paralysis may occur in the postoperative period 
even after successful reversal of the block at the end of anes-
thesia and surgery.30–32 Therefore, we monitored all patients 
during the early postoperative period using acceleromyo-
graphic measurements and clinical tests. We did not observe 
PORNB in our postanesthesia care unit.
In the present investigation, sevoflurane anesthesia was 
maintained until recovery of the TOF ratio to 1.0. Several 
studies have noted that antagonism of residual NMB with 
anticholinesterases was prolonged by anesthetizing con-
centrations of volatile anesthetics.14,33 The enhancement of 
pipecuronium block by volatile drugs has been published as 
well.9,10,34 However, when sugammadex was administered, 
the reversal was satisfactory under sevoflurane anesthesia, 
thus supporting those findings that sevoflurane has little 
influence on the efficacy of sugammadex.13,24 Indeed, in our 
patients, 1.0 and 2.0 mg/kg of sugammadex produced aver-
age reversal times of 2.3 and 1.7 minutes, respectively. Similar 
times (3.3 and 1.7 minutes, respectively) were measured by 
others when a moderate rocuronium-induced block was 
reversed with sugammadex during propofol anesthesia.23,24
There may be both chemical and pharmacological rea-
sons to explain the efficiency of sugammadex for the rever-
sal of pipecuronium. First, the value of affinity constant (Ka) 
for pipecuronium (161 ± 28 × 106 M−1) is about 10 or 18 times 
greater than for rocuronium or vecuronium, respectively, 
and 60 times greater than the Ka for pancuronium.b The 
affinity constant (also known as the association constant) 
is a numerical measure of the bonding affinity of 2 mole-
cules at equilibrium. In other words, this constant describes 
the molecular binding strengths between the NMBA and 
sugammadex. Since the Ka for sugammadex-pancuronium 
is 60 times less than for sugammadex-pipecuronium, the 
present observations cannot be extrapolated to sugamma-
dex reversal of pancuronium. Second, pipecuronium is 6 to 
7 times more potent than rocuronium,9,17 and its molecular 
weight is also 30% greater than the molecular weight of 
rocuronium, thus fewer pipecuronium than rocuronium 
molecules are required to induce an equivalent level of 
bAvailable at: www.pmda.go.jp/english/service/pdf/drugs/bridion_jan2010_e.
pdf (Page 15, paragraph 3.(i).A.(1).1).
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NMB. Since the binding of the relaxant by sugammadex 
is a one-to-one molecular interaction, the encapsulation of 
almost all of the pipecuronium molecules requires relatively 
small amounts of sugammadex.
Following the introduction of atracurium and 
vecuronium in the mid-1980s, the clinical use of traditional, 
long acting drugs such as pancuronium has dramatically 
declined. This transpired because of the recognition that 
long-acting drugs were associated with a higher incidence 
of RPONB35 and the resultant potential for adverse clinical 
consequences.36 It is now apparent, however, that residual 
paresis following the administration of intermediate-acting 
drugs is still common.37–39 The duration of effect of these 
drugs is longer than most clinicians realize,31 and reversal 
of residual block with anticholinesterase inhibitors is often 
slow and incomplete.15
The routine pharmacologic reversal of blocks from all 
intermediate-acting muscle relaxants has been suggested 
and objective monitoring strongly advised.40 Repetitive 
bolus or infusion administration of intermediate-acting 
relaxants for surgery of long duration endorsed the occur-
rence of RPONB.41 Therefore, one must carefully consider 
not only the expected duration of action of a muscle relax-
ant but also the facility of its reversal and its possible 
side effects (histamine release, tachycardia, hypertension, 
hypotension, allergy, or active metabolites). For those clini-
cians who have access to sugammadex and pipecuronium 
the “requirement” for using short- or intermediate-acting 
NMBAs for brief procedures is no longer absolute. These 
data can be used to argue that pipecuronium can safely 
be administered for any procedure if one can anticipate 
spontaneous recovery to a TOFC-2. Thus, a single 200 mg 
vial sugammadex might be adequate for even the mor-
bidly obese, provided that the TOFC has returned to a 
value of 2.
Limitations
This study has not investigated the efficacy of sugamma-
dex in reversing profound, deep and shallow pipecuronium 
block. Antagonism after repetitive pipecuronium adminis-
tration during surgery of extreme long duration (6–8 hours) 
was not studied either. Further investigation is needed to 
establish the full profile of antagonism of pipecuronium-
induced NMB with sugammadex. Although the antagonism 
of pipecuronium was perfectly adequate in all 9 patients 
who received 1.0 mg/kg of sugammadex, data from a larger 
sample size would be highly desirable before this dose can 
be recommended with confidence for pipecuronium rever-
sal at TOFC-2.
In conclusion, we provide evidence on the adequacy 
of reversal of moderate pipecuronium-induced NMB with 
sugammadex under sevoflurane maintenance anesthesia. 
We demonstrate that once the TOFC has spontaneously 
returned to 2 responses following pipecuronium admin-
istration, it is unnecessary to administer sugammadex in 
a dose larger than 2.0 mg/kg in order to achieve satisfac-
tory neuromuscular recovery, and even this may be more 
than sufficient. Our conclusions mandate that the clinician 
needs to monitor neuromuscular function. A conventional 
(qualitative) peripheral nerve stimulator is sufficient for 
the detection of a TOFC-2 degree of NMB. E
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